share_log

Insiders Sold CN¥11m Of Peijia Medical Stock Possibly Sending Warning Sign

Insiders Sold CN¥11m Of Peijia Medical Stock Possibly Sending Warning Sign

業內人士出售了1100萬元人民幣的培佳醫療股票,可能發出警告信號
Simply Wall St ·  2023/11/20 17:51

Despite a 14% gain in Peijia Medical Limited's (HKG:9996) stock price this week, shareholders shouldn't let up. Although prices were relatively low, insiders chose to sell CN¥11m worth of stock in the past 12 months. This could be a sign of impending weakness.

儘管本週培佳醫療有限公司(HKG: 9996)的股價上漲了14%,但股東們不應放鬆。儘管價格相對較低,但在過去的12個月中,內部人士選擇出售價值1100萬元人民幣的股票。這可能是即將出現疲軟的跡象。

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.

雖然我們絕不會建議投資者僅根據公司董事的所作所爲做出決定,但邏輯要求你應該注意內部人士是在買入還是賣出股票。

See our latest analysis for Peijia Medical

查看我們對培佳醫療的最新分析

Peijia Medical Insider Transactions Over The Last Year

培佳醫療過去一年的內幕交易

In the last twelve months, the biggest single sale by an insider was when the Executive Director & Company Secretary, Hong Ye, sold HK$3.1m worth of shares at a price of HK$11.09 per share. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. It's of some comfort that this sale was conducted at a price well above the current share price, which is HK$7.95. So it may not tell us anything about how insiders feel about the current share price. Hong Ye was the only individual insider to sell over the last year.

在過去的十二個月中,內部人士最大的一次出售是執行董事兼公司秘書Hong Ye以每股11.09港元的價格出售了價值310萬港元的股票。雖然我們通常不喜歡看到內幕拋售,但更令人擔憂的是銷售是否以較低的價格進行。令人欣慰的是,此次出售的價格遠高於目前的股價,即7.95港元。因此,它可能無法告訴我們內部人士對當前股價的看法。Hong Ye是去年唯一一位賣出的個人內部人士。

Hong Ye divested 1.04m shares over the last 12 months at an average price of CN¥10.71. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

在過去的12個月中,宏業剝離了104萬股股票,平均價格爲10.71元人民幣。你可以在下面看到過去 12 個月內幕交易(由公司和個人進行的)的直觀描述。如果你點擊圖表,你可以看到所有的個人交易,包括股價、個人和日期!

insider-trading-volume
SEHK:9996 Insider Trading Volume November 20th 2023
香港交易所:9996 內幕交易量 2023 年 11 月 20 日

I will like Peijia Medical better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

如果我看到一些大筆的內幕買入,我會更喜歡培佳醫療。在我們等待的同時,請查看這份免費名單,列出了最近有大量內幕買入的成長型公司。

Does Peijia Medical Boast High Insider Ownership?

培佳醫療是否擁有很高的內幕所有權?

For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. Peijia Medical insiders own about HK$164m worth of shares. That equates to 3.1% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

對於普通股股東來說,值得檢查一下公司內部人士持有多少股票。我們通常希望看到相當高的內部所有權水平。培佳醫療內部人士擁有價值約1.64億港元的股票。這相當於該公司的3.1%。當然,我們在其他地方看到了更高的內幕所有權水平,但這些持股足以表明內部人士與其他股東保持一致。

So What Does This Data Suggest About Peijia Medical Insiders?

那麼,這些數據對培佳醫學內幕人士有何啓示呢?

It doesn't really mean much that no insider has traded Peijia Medical shares in the last quarter. While we feel good about high insider ownership of Peijia Medical, we can't say the same about the selling of shares. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Peijia Medical. To assist with this, we've discovered 1 warning sign that you should run your eye over to get a better picture of Peijia Medical.

上個季度沒有內部人士交易過培佳醫療的股票,這並不意味着什麼。儘管我們對培佳醫療的高內幕所有權感到滿意,但對於出售股票,我們不能說同樣的話。除了了解正在進行的內幕交易外,識別培佳醫療面臨的風險也是有益的。爲了幫助解決這個問題,我們發現了 1 個警告信號,你應該仔細觀察才能更好地了解 Peijia Medical。

Of course Peijia Medical may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

當然,培佳醫療可能不是最值得買入的股票。因此,您可能希望看到這些免費的高質量公司集。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論